Calimmune

About:

Calimmune is a clinical-stage gene therapy company.

Website: http://calimmune.com

Top Investors: RA Capital Management, Alexandria, Translational Accelerator

Description:

Calimmune is a clinical-stage gene therapy company. The company’s lead therapeutic candidate, is a gene-based therapy engineered to control HIV infection and to protect individuals with HIV from progressing to AIDS. The therapy is currently being evaluated in Phase I/II studies. Cal-1 is designed to reduce production of CCR5, a protein on the surface of white blood cells that plays a critical role in enabling HIV to infect cells. It also has a second mechanism aimed at preventing viral fusion, the process by which the virus enters the cell. This dual approach was shown to be effective against broad strains of HIV in pre-clinical studies.